Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MiMedx Group ( (MDXG) ) has provided an announcement.
MiMedx Group reported a 3% increase in net sales for Q3 2024, reaching $84 million, driven by strong product contributions despite some sales team turnover and product declines. The company expects 2024 net sales growth to hit the high single digits, emphasizing strategic priorities and potential growth in placental tissue products. Adjusted EBITDA rose to $18 million, with a 22% margin, showcasing robust financial health amid market challenges.
Find detailed analytics on MDXG stock on TipRanks’ Stock Analysis page.